The SELECT trial demonstrated a clear cardiovascular protection associated with semaglutide use, which could explain its ...

Semaglutide, a GLP-1R agonist developed by Denmark’s Novo Nordisk as Ozempic, initially for type 2 diabetes, and marketed ...

If all the Instagram posts and podcasts filling my feed are any indication, lots of 40- and 50-something women are spending ...

Indian drugmaker, Cipla Ltd, sees GLP-1 drugs, used to treat type-2 diabetes and obesity, as a significant new therapy opportunity in the Indian market.

WOMEN and older adults who use increasingly popular weight-loss drug semaglutide could protect themselves from a common side ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Table of Contents The Real Story Behind Your Changing Body Making Every Bite Count When You’re Eating Less Your Brain […] The ...

Women and older adults using semaglutide, a popular anti-obesity medication, may face a heightened risk of muscle loss. A ...

People who took semaglutide over a slower, more flexible schedule were significantly less likely to experience nausea and to ...

India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...

Cipla reports a 10% YoY rise in Q1FY26 net profit, driven by strong performance in consumer healthcare and generics. The ...

Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.